Detail akcie Abbott Labs online

Business Summary: Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Abbott Laboratories revenues increased 6% to $44.33B. Net income decreased 51% to $6.52B. Revenues reflect Medical Devices segment increase of 13% to $21.39B, Established Pharmaceutical Products segment increase of 7% to $5.54B, Nutritionals Products segment increase of less than 1% to $8.45B, All other Countries segment increase of 8% to $15.98B, United States segment increase of 5% to $17.13B.